Filter by Category: Antimicrobial Surveillance

Antimicrobial activity of telavancin tested in vitro against a global collection of gram-positive pathogens, including multidrug-resistant isolates (2015-2017)

Antimicrobial activity of telavancin tested in vitro against a global collection of gram-positive pathogens, including multidrug-resistant isolates (2015-2017). by Duncan LR, Sader HS, Huband MD, Flamm RK and Mendes RE published in Microb. Drug Resist.: in press, 2020.

Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America

Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America. by Sader HS, Carvalhaes CG, Streit JM, Castanheira M and Flamm RK published in Int. J. Infect. Dis. 2020; 91: 32-37

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. by Sader HS, Mendes RE, Pfaller MA and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (5): 1306-1310

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK published in J. Glob. Antimicrob. Resist.: in press, 2019.

Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK 5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections

Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK 5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1598

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018. Lead Author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2217

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2192

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1589

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1583

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1445